Veterinary Pharmaceutical Solutions
Veterinary Pharmaceutical Solutions, often referred to as VPS, is a leading provider of innovative veterinary pharmaceuticals headquartered in the United States. Established in 2005, the company has made significant strides in the veterinary industry, focusing on the development and distribution of high-quality medications for companion animals and livestock. With a strong presence across North America and expanding operations in Europe, VPS is renowned for its unique formulations and commitment to animal health. Their core product offerings include anti-infectives, analgesics, and vaccines, all designed to enhance the well-being of animals while ensuring compliance with regulatory standards. VPS has earned a notable reputation for its dedication to research and development, positioning itself as a trusted partner for veterinarians and animal health professionals. Through continuous innovation and a customer-centric approach, Veterinary Pharmaceutical Solutions remains at the forefront of the veterinary pharmaceutical market.
DitchCarbon Score
How does Veterinary Pharmaceutical Solutions's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Veterinary Pharmaceutical Solutions's score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Veterinary Pharmaceutical Solutions's reported carbon emissions
In 2018, Veterinary Pharmaceutical Solutions reported total carbon emissions of approximately 5,333,241 kg CO2e. This figure includes 3,931,064 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 1,402,177 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Comparatively, emissions in 2017 were about 3,937,200 kg CO2e, with Scope 1 emissions at 2,238,330 kg CO2e and Scope 2 emissions at 1,698,866 kg CO2e. In 2016, the total emissions were approximately 4,574,420 kg CO2e, comprising 2,539,110 kg CO2e from Scope 1 and 2,035,306 kg CO2e from Scope 2. Despite these figures, Veterinary Pharmaceutical Solutions has not established specific reduction targets or initiatives, nor do they participate in the Science Based Targets initiative (SBTi). The absence of a climate pledge indicates a need for further commitment to climate action within the industry context. The data presented is not cascaded from any parent organisation, reflecting the company's independent reporting on its emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | |
|---|---|---|---|
| Scope 1 | 2,539,110 | 0,000,000 | 0,000,000 |
| Scope 2 | 2,035,306 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Veterinary Pharmaceutical Solutions is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
